{"filing":{"accession_number":"0001599298-26-000054","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"smmt-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000054/smmt-20260610.htm"},"events":[{"id":10837,"run_id":9507,"accession_number":"0001599298-26-000054","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the results of Summit Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026, with detailed voting tabulations for four proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, non-binding advisory vote on named executive officer compensation, and approval of a stock incentive plan amendment to increase shares by 8,000,000. All proposals were approved by the requisite stockholder vote, making this a clear shareholder vote results disclosure.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7254,"accession_number":"0001599298-26-000054","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Summit Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026, with detailed voting tabulations for four proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, non-binding advisory vote on named executive officer compensation, and approval of a stock incentive plan amendment to increase shares by 8,000,000. All proposals were approved by the requisite stockholder vote, making this a clear shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:21:02.202585+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7254,"accession_number":"0001599298-26-000054","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Summit Therapeutics' 2026 Annual Meeting of Stockholders held on June 10, 2026, with detailed voting tabulations for four proposals: election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, non-binding advisory vote on named executive officer compensation, and approval of a stock incentive plan amendment to increase shares by 8,000,000. All proposals were approved by the requisite stockholder vote, making this a clear shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:21:02.202585+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-06-12"}]}